Increasing evidence suggests that inhibition of JAK expression can treat inflammation or cancer that is dependent on JAK/STAT pathway activation, and such, this has attracted an increasing number of scholars and pharmaceutical companies to invest in the development of small-molecule inhibitors targeting JAK [102]. This evidence concerns the gene SOAT1 and cancer.